Cathepsin C Biomarker for Neuropathic Pain Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological pain therapies for chronic pain are unsatisfactory in terms of efficacy and safety, and there is a need for novel options for treatment and diagnosis that align with the advancing understanding of neurobiology.
Innovation Solution
The use of Cathepsin C or its functional fragments to identify compounds that modulate pain, leveraging the correlation between Cathepsin C expression and pain susceptibility in mouse models of neuropathic pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmacological pain therapies are used, then pain relief is provided, but safety and efficacy are unsatisfactory
Solution Approach 1:
The patent changes the fundamental parameter of pain treatment by shifting from symptomatic management to targeted molecular intervention. By identifying Cathepsin C as a specific biomarker and therapeutic target associated with pain susceptibility, the invention enables precise parameter-based treatment strategies that modify the underlying molecular mechanisms rather than merely masking symptoms, thereby improving efficacy while reducing side effects through selective action on pain pathways.
Solution Approach 2:
The patent introduces Cathepsin C as an intermediary biomarker that mediates between genetic predisposition and pain phenotype. This intermediary enables indirect targeting of pain pathways through measurable molecular markers, allowing for safer and more effective treatments by first identifying and then modulating the intermediary Cathepsin C expression levels rather than directly interfering with complex pain circuits.
2Reliability
If novel pain treatment options are developed, then treatment efficacy is improved, but the complexity of identifying new targets increases
Solution Approach 1:
The patent extracts Cathepsin C as a discrete, isolatable target from the complex web of pain-related genes and proteins. By focusing on this single extracted biomarker that shows strong correlation with pain susceptibility, the invention simplifies the target identification process while maintaining high treatment efficacy potential, avoiding the need to simultaneously analyze and intervene in multiple complex pain pathways.
Solution Approach 2:
The patent segments the complex field of pain research into distinct functional modules by identifying Cathepsin C as a specific segment within the broader pain pathway network. This segmentation allows researchers to study and target this particular segment independently, reducing the overall complexity of pain target identification while preserving the ability to develop effective treatments through focused intervention on this segmented target.
3Adaptability or versatility
If Cathepsin C is used as a target for identifying pain-modulating compounds, then novel therapeutic options are discovered, but the time required for drug development increases
Solution Approach 1:
The patent performs preliminary action by establishing Cathepsin C as a validated target with demonstrated correlation to pain susceptibility before initiating compound screening. This preliminary validation creates a pre-approved target framework that accelerates subsequent drug development stages, as the target's relevance is already confirmed, eliminating the need for extensive target validation during the drug discovery process and reducing overall development time.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Present invention concerns the use of Cathepsin C. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain.